Metabolic effects of fructose and the worldwide increase in obesity.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic, animal, and human studies without systematic review methodology
PubMed 20086073 · doi:10.1152/physrev.00019.2009
What was done
This narrative review synthesized evidence on fructose metabolism, contrasting its hepatic processing with glucose and assessing animal and human data regarding high fructose intake, sweetened beverage consumption, and high-fructose corn syrup versus sucrose in relation to obesity and metabolic disorders.
What was found
The abstract reports no quantitative figures. Chronic high fructose intake in rodents causes hepatic and extrahepatic insulin resistance, obesity, type 2 diabetes, and hypertension. In humans, high fructose intake impairs hepatic insulin sensitivity and causes dyslipidemia, proposed to occur via de novo lipogenesis, lipotoxicity, oxidative stress, and hyperuricemia. Sweetened beverage intake associates with higher energy intake, increased weight, and cardiometabolic disorders, but there is no unequivocal evidence that moderate fructose intake directly causes metabolic harm or that high-fructose corn syrup differs in risk from sucrose.
Why it matters
It contextualizes the biological plausibility of fructose-induced metabolic disruption at high doses while differentiating established high-dose effects from unproven harms of moderate intake or high-fructose corn syrup relative to sucrose.
Limits
The paper is a narrative review with no systematic search criteria, quality appraisal, or study counts reported in the abstract. Causal evidence for severe metabolic dysfunction relies largely on rodent models and supra-physiological human intakes rather than moderate dietary exposures.
Cited by
- contradicts About 70% of ingested fructose is absorbed through the portal vein and metabolized by the liver into uric acid and triglycerides.